The number of Americans diagnosed with Alzheimer’s each year is expected to double by 2060, with the majority of cases affecting women.

Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...

Neuroscientists have taken a major step toward detecting Alzheimer’s disease in its earliest stages—long before memory loss ...

A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.

A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.

SCIENTISTS have spent decades trying to understand what causes dementia. Is it alcohol? Obesity? Or are some of us simply ...

A groundbreaking study from the Centre for Addiction and Mental Health (CAMH) in Canada has revealed that an experimental ...

Dementia is one of the leading causes of death in Australia but a new finding could revolutionise detection and treatment. American researchers analysed health data from 24,000 patients living with ...

The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

The damage alcohol causes to the brain is both direct and indirect. It directly harms brain cells and interferes with ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...